pembrolizumab + chemotherapy +/- bevacizumab PD-L1 Expression (CPS >= 1) Cervical Carcinoma Metastatic, +1 more state bevacizumab, +2 more drugs chemotherapy, +2 more types
pembrolizumab PD-L1 Expression (CPS >= 1) Head and Neck Squamous Cell Carcinoma Metastatic, +2 more states First line pembrolizumab immunotherapy
pembrolizumab PD-L1 Expression (CPS >= 1) Cervical Carcinoma Metastatic, +1 more state Subsequent line pembrolizumab immunotherapy
nivolumab PD-L1 Expression (CPS >= 1) Cervical Carcinoma Metastatic, +1 more state Subsequent line nivolumab immunotherapy
pembrolizumab PD-L1 Expression (CPS >= 1) Cervical Carcinoma Metastatic, +1 more state Subsequent line pembrolizumab immunotherapy
pembrolizumab PD-L1 Expression (CPS >= 1) Vulvar Squamous Cell Carcinoma Advanced, +2 more states Second line pembrolizumab immunotherapy
pembrolizumab + paclitaxel + (carboplatin or cisplatin) +/- bevacizumab PD-L1 Expression (CPS >= 1) Cervical Carcinoma Metastatic, +1 more state First line bevacizumab, +4 more drugs chemotherapy, +2 more types
MT-6402 PD-L1 Expression (CPS >= 1), +4 more biomarkers Non-Small Cell Lung Carcinoma Advanced MT-6402 immunotherapy
Cancer Search
